Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

BACKGROUND: Adults aged ≥ 60 years are often underrepresented in atopic dermatitis (AD) clinical trials; age-related comorbidities may impact treatment efficacy and safety. OBJECTIVE: The aim was to report dupilumab efficacy and safety in patients aged ≥ 60 years with moderate-to-severe AD. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverberg, Jonathan I., Lynde, Charles W., Abuabara, Katrina, Patruno, Cataldo, de Benedetto, Anna, Zhang, Haixin, Thomas, Ryan B., Bégo-Le-Bagousse, Gaëlle, Khokhar, Faisal A., Vakil, Jignesh, Marco, Ainara Rodríguez, Levit, Noah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195762/
https://www.ncbi.nlm.nih.gov/pubmed/36808602
http://dx.doi.org/10.1007/s40257-022-00754-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195762/
https://www.ncbi.nlm.nih.gov/pubmed/36808602
http://dx.doi.org/10.1007/s40257-022-00754-4

Ejemplares similares